The study's main purpose is to assess the vaccine's safety and the immune response that develops in vaccinated people. T clinical trials

VITAL01: A study of a new vaccine against Lassa fever in adults aged 18-55 years

This study is testing a new vaccine for Lassa fever, a serious illness found in West Africa. We want to see if the vaccine is safe and helps your body build protection. Healthy adults aged 18-55 can take part at the University of Oxford. Your help could lead to a vital vaccine.